At Zosano Pharma, the safety and well-being of our employees and the community remain our highest priority. In response to the spread of COVID-19, we are addressing the issue with the seriousness it deserves.
Live at the Speed of Life
Zosano Pharma is a commercially focused biopharmaceutical company enabling the systemic administration of therapeutics and other bioactive molecules to patients using our proprietary intracutaneous microneedle patch system. We have pioneered a novel paradigm for delivering molecules typically administered parenterally, where the inconvenience and pain associated with subcutaneous, intravenous or other complex administrations present barriers to compliance. Our strengths lie in our diverse team of industry veterans with proven drug and device development and significant commercialization experience.
Our lead clinical asset, Qtrypta*™ (zolmitriptan intracutaneous microneedle system), for the acute treatment of migraine with or without aura in adult patients, is currently under review by FDA. We expect that Qtrypta will be available, if approved, in 2021.
With our proprietary intracutaneous microneedle patch system, therapeutic blood levels are obtained more rapidly than with oral administration.
Ready. Set. Apply. Three easy steps for administration.
Zosano Pharma’s investigational migraine treatment, M207 (the proposed commercial name, QTRYPTA), is a novel formulation of zolmitriptan, a drug used orally and nasally to effectively and safely treat MIGRAINE, administered via the Company’s proprietary intracutaneous microneedle-array drug-delivery system. The same formulation, development name C213, is being investigated as a potential treatment to provide rapid relief of cluster headache. This candidate is currently in Phase 2 clinical trials.
*Qtrypta (zolmitriptan intracutaneous microneedle system) is the proposed commercial tradename.